A109820 Stock Overview
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
GeneMatrix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,555.00 |
| 52 Week High | ₩5,490.00 |
| 52 Week Low | ₩2,380.00 |
| Beta | 0 |
| 1 Month Change | -11.90% |
| 3 Month Change | -4.13% |
| 1 Year Change | -49.20% |
| 3 Year Change | -82.68% |
| 5 Year Change | -33.55% |
| Change since IPO | -14.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| A109820 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 1.0% | 2.9% | 2.7% |
| 1Y | -49.2% | 10.0% | 5.8% |
Return vs Industry: A109820 underperformed the KR Biotechs industry which returned 10% over the past year.
Return vs Market: A109820 underperformed the KR Market which returned 5.8% over the past year.
Price Volatility
| A109820 volatility | |
|---|---|
| A109820 Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A109820 has not had significant price volatility in the past 3 months.
Volatility Over Time: A109820's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Soook Kim | www.genematrix.net |
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also provides biochemical diagnostics, such as special chemistry and general chemistry, that includes semi and full auto analyer, and calibrators and controls.
GeneMatrix Inc. Fundamentals Summary
| A109820 fundamental statistics | |
|---|---|
| Market cap | ₩52.10b |
| Earnings (TTM) | -₩2.09b |
| Revenue (TTM) | ₩4.72b |
0.0x
P/S Ratio0.0x
P/E RatioIs A109820 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A109820 income statement (TTM) | |
|---|---|
| Revenue | ₩4.72b |
| Cost of Revenue | ₩2.94b |
| Gross Profit | ₩1.79b |
| Other Expenses | ₩3.88b |
| Earnings | -₩2.09b |
Last Reported Earnings
Sep 30, 2019
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A109820 perform over the long term?
See historical performance and comparison